Mito Foundation hosts Autosomal Dominant Optic Atrophy (ADOHA) Webinar on 23rd February 2026

Have you or those you work with or care for been impacted by Autosomal Dominant Optic Atrophy (ADOA) or ADOA+? 

Understanding ADOA Webinar

On Monday, 23^rd February 2026, The Mito Foundation will be hosting this webinar to provide information about ADOA in a way that empowers people affected. The event will include information about the signs and symptoms of ADOA, the role of genetic testing and progress being made in research.

While ADOA is a type of mitochondrial disease, Mito Foundation is only connected to a small number of Australians living with ADOA. These connections help to:
• Support research projects, including clinical trials for new treatment options
• Offer support services, including assistance with NDIS

What is ADOA?
Autosomal Dominant Optic Atrophy (ADOA) is a genetic condition that causes progressive damage to the optic nerves. It also often causes sensorineural hearing loss. It typically results in gradual loss of central and colour vision, often beginning in childhood or early adulthood. ADOA is often caused by changes to the OPA1 gene, and is considered a type of mitochondrial disease. ADOA is inherited in an autosomal dominant pattern, meaning it can be passed from an affected parent to their child
The Mito Foundation has received a grant from PYC Therapeutics, who are developing a new therapy for people with ADOA. PYC Therapeutics will not be involved in decisions on event content or other details. The event will not focus on their trial or product specifically.